Novo Nordisk-partnered Aspect develops bioprinted tissue therapeutics designed t...
The company did not expect to resolve concerns related to manufacturing and the ...
Boehringer Ingelheim’s For Generations framework is all in on sustainability for...
The Association of the British Pharmaceutical Industry (ABPI) also called out No...
China's NMPA approved Antengene’s new indication of XPOVIO for adults with relap...
iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase...
iTeos will receive $35m from GSK as the first patient is dosed in the Phase III ...
The Susvimo eye implant is filled with Lucentis, which delivers the therapy cont...
SciRhom has secured €63m ($70m) in a Series A funding round to develop iRhom2-ta...
Taiho has exercised an option for an exclusive licence for Arcus Biosciences’ qu...
Ligand Pharmaceuticals has announced a definitive agreement for the acquisition ...
Moderna and Mitsubishi Tanabe have entered into a collaboration to jointly promo...
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials...
Dalfampridine IR is under clinical development by Solaxa and currently in Phase ...
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I f...
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I f...
